COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
A total of 820 participants, consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged =50 years 2. In good health or have well-controlled or mild-moderate comorbidity, as determined by a trial clinician 3. Willing and able to give written informed consent for participation in the trial 4. Those of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation 5. Able and willing to comply with all trial requirements, in the Investigator's opinion 6. Willing to allow their General Practitioner and consultant, if appropriate, to be notified of participation in the trial 7. Willing to allow investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures 8. Agreement to refrain from blood donation during the course of the study
Exclusion criteria
Exclusion criteria: 1. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine) 2. Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on the interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines) 3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines 4. Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent severe infections, or use of immunosuppressant medication within the past 6 months, with the exception of topical steroids or short-term oral steroids (course lasting =14 days) 5. History of allergic disease or reactions likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the SmPC-listed ingredients of the Pfizer vaccine) 6. Any history of anaphylaxis 7. Pregnancy, lactation, or willingness/intention to become pregnant within 3 months post boost vaccine 8. Current diagnosis of or treatment for cancer (with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ) 9. Bleeding disorder (e.g. factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture 10. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran, and edoxaban) 11. Suspected or known current alcohol or drug dependency 12. Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data 13. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness (mild/moderate well-controlled comorbidities are allowed) 14. History of active or previous auto-immune neurological disorders (e.g. multiple sclerosis, Guillain-Barre syndrome, transverse myelitis). Bell’s palsy will not be an exclusion criterion 15. History of laboratory-confirmed COVID-19 prior to enrolment (history of SARS-CoV-2 detection by PCR or antibody to SARS-CoV-2) 16. Significant renal or hepatic impairment 17. Scheduled elective surgery during the trial 18. Life expectancy of <6 months 19. Participation in another research trial involving an investigational product in the past 12 weeks 20. Insufficient level of English language to undertake all study requirements in the opinion of the Investigators 21. If at Visit 1 Screening & Vaccination the volunteer has either of the following, they will not be enrolled that day, however, they may be considered for enrolment later in the trial; if they recover in sufficient time: 21.1. Acute respiratory illness (m
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity of COVID-19 vaccines boosted at day 28 in seronegative participants measured using serum level of anti-spike immunoglobulins using ELISA at 56 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Immunogenicity of COVID-19 vaccines in seronegative participants across all dosing intervals measured using serum level of anti-spike immunoglobulins using ELISA at 4 weeks post-boost (56 days for 28-day boost cohort and 112 days for 84-day boost cohort) 2. Safety of heterologous prime-boost COVID-19 vaccines measured using the incidence of serious adverse events and adverse events of special interest measured by electronic diary card and participant reporting throughout the study 3. Further characterisation of immunogenicity measured using the following: 3.1. Anti-spike immunoglobulins using ELISA at 4 weeks post-boost (56 days for 28-day boost cohort and 112 days for 84-day boost cohort) 3.2. Anti-spike immunoglobulins using ELISA at baseline, 7, 28, 35, 84, 112, 182, and 364 days 3.3. Neutralising antibodies against SARS-CoV-2 using viral neutralizing assay at baseline, 28, 56, 84, 112, 182, and 364 days 3.4. Anti-nucleocapsid immunoglobulins by immunoassay at baseline, 28, 56, 84, 112, 182, and 364 days 3.5. Pseudo neutralising antibodies at baseline, 28, 56, 84, 112, 182, and 364 days 3.6. Cellular immune responses by ELISpot at baseline, 14, 28, 42, 56, 84, 112, 182, and 364 days 3.7. Cellular immune responses by intracytoplasmic cytokine staining (ICS) (Th1/Th2) at baseline, 14, and 42 days 4. Reactogenicity and safety measured using the following: 4.1. Solicited local reactions measured by electronic diary card at 7 days after each immunisation 4.2. Solicited systemic reactions measured by electronic diary card at 7 days after each immunisation 4.3. Unsolicited reactions at 28 days after each immunisation 4.4. Medically attended adverse reactions measured by electronic diary card at up to 3 months post-boost 4.5. Chan | — |
Countries
England, United Kingdom
Contacts
Public ContactCom-COV study team
Outcome results
None listed